Steve Conlan is Professor of Molecular and Cell Biology, head of Reproductive Biology and Gynaecological Oncology research, Director of Strategic Partnerships for the College, and Director of the Centre for NanoHealth.
Prof Conlan’s research focuses on the application of molecular, cellular and nano biology approaches to understanding gynaecological pathologies including infertility and cancer due to abnormalities in the endometrium (the lining of the womb) and ovaries. He has a particular interest in the impact of aberrant transcription and epigenetic processes in these diseases. His aim is to work towards biomarkers and points of intervention that can be developed for clinical use.
His interest in NanoHealth centres around the characterisation of cellular interactions at the nanoscale. The group have developed the application of Atomic Force Microscopy (AFM) for biophysical analysis of live cells and tissue, including cancer cells, stem cells and cartilage.
He is a Director of the £22 Million Centre for NanoHealth at Swansea University, which is focused on regenerative medicine, nano-genotoxicology, the development of nano-enabelled devices and characterisation techniques for the detection and monitoring of disease.
Prof Conlan works closely with the life science and healthcare industrial sector, and has active collaborations with SMEs and multinational companies. As Director of Strategic Partnerships, and member of the University’s Internationalisation Strategy Group, he leads strategic collaborative initiatives with Grenoble - France, Houston - US and Suzhou and Wuhan – China. Prof Conlan holds an honorary consultant position in the Abertawe Bro Morgannwg NHS Board, working with clinical colleagues in Singleton Hospital Swansea and The Princess of Wales Hospital Bridgend. He is a Senior Affiliate Member of The Methodist Hospital Research Institute, Houston Texas, and Distinguished Professor at Xi'an Jiaotong University, Suzhou Academy, China.